After successfully out licensing its novel compound for the treatment of narcolepsy (ADX-N05) to Jazz Pharmaceuticals in January 2014, Aerial is focusing its efforts on the development of Prostatic Acid Phosphatase (PAP), for the treatment of acute post-surgical pain and chronic pain

PAP is a unique large molecule that works on the adenosine pathway for the management of acute and chronic pain.  With IND enabling studies underway, the current estimates are to file the IND Q2 of 2014.